Cencora, Inc. COR SPX

Healthcare · Medical Distribution · United States

https://www.cencora.com

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Market & Price

Market Cap

$52.41B

Current Price

$269.36

High / Low (52W)

$373.25 / $252.16

Beta

0.65

Valuation

Stock P/E

20.66

Industry PE

23.65

Forward P/E

13.62

PEG Ratio

0.64

Book Value

$17.46

Price to Book

15.42

P/S

0.16

EV/EBITDA

12.36

Dividend Yield

0.89%

Profitability & Returns

ROCE

14.27%

ROE

107.13%

ROA

3.49%

Profit Margin

0.78%

Op Margin

1.72%

EPS (Latest Qtr)

$8.40

EPS (TTM)

$13.04

Balance Sheet & Liquidity

Debt/Equity

4.21

Quick Ratio

0.48

Current Ratio

0.95

Debt

$15.09B

Total Assets

$76.59B

Current Assets

$52.24B

Working Capital

$-5.58B

Ownership

Promoter Holding

4.23%

Chg in Prom Hold

0.00%

FII / Inst Holding

98.11%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$65.51B

Total Revenue (TTM)

$328.68B

EBITDA

$5.30B

Free Cash Flow

$-318.25M

Operating Cash Flow

$2.28B

Shares Outstanding

194.56M

Gross Margin

3.80%

Payout Ratio

17.62%

Growth (CAGR)

Revenue 5Y

10.43%

Profit 5Y

-2.92%

Revenue (YoY)

3.80%

Earnings (YoY)

128.30%

PROS

Strong return on equity of 107.1%.
Compounding revenue at 10.4% over 5 years.

CONS

Earnings shrank at -2.9% CAGR over 5 years.
Trading 27.8% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	COR Cencora, Inc. SPX	269.36	20.66	$52.41B	0.89%	14.27%	107.13%	10.43%	-2.92%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Dec 2021	Mar 2022	Jun 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	34.23B	35.47B	36.71B	35.70B	36.88B	37.56B	38.17B	37.15B	38.71B	39.12B	40.47B	41.03B	43.14B	43.30B	45.39B	43.32B	45.24B	45.64B	47.86B	47.42B	45.37B	49.24B	52.52B	49.15B	53.41B	59.63B	57.72B	60.06B	62.85B	63.46B	66.95B	72.25B	68.41B	74.24B	-	75.45B	80.66B	83.73B	85.93B	78.36B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72.39B	77.76B	80.77B	82.86B	74.77B
Gross Profit	891.46M	973.57M	964.88M	1.08B	1.11B	1.12B	1.04B	1.26B	1.08B	1.17B	1.11B	1.26B	1.21B	1.03B	1.30B	1.42B	1.23B	1.18B	1.23B	1.39B	1.23B	1.35B	1.45B	1.53B	1.89B	2.06B	2.24B	2.02B	2.15B	2.30B	2.26B	2.47B	2.54B	2.41B	-	3.06B	2.91B	2.95B	3.07B	3.59B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.86B	1.93B	2.01B	2.06B	2.23B
Operating Income	334.18M	538.48M	-178.14M	950.48M	528.63M	224.80M	399.99M	624.98M	170.38M	-135.00M	418.97M	481.42M	389.19M	154.10M	477.82M	47.56M	406.69M	179.84M	263.44M	309.51M	404.83M	-6.11B	547.23M	624.35M	620.73M	644.40M	780.16M	487.30M	633.14M	560.52M	670.13M	822.88M	553.26M	672.48M	-	1.20B	980.24M	945.94M	1.02B	1.36B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.32B	1.27B	186.31M	1.07B	2.51B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	132.32M	116.90M	109.36M	93.36M	154.34M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	928.66M	896.28M	-187.04M	708.64M	2.09B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	211.24M	206.53M	146.03M	142.51M	459.04M
Net Income	213.36M	363.12M	329.64M	603.45M	349.15M	145.69M	247.25M	411.47M	50.35M	-344.59M	861.85M	287.45M	275.81M	233.29M	393.65M	27.14M	301.96M	132.62M	187.64M	960.28M	289.44M	-4.85B	374.85M	435.27M	292.12M	449.11M	548.01M	406.96M	479.75M	435.40M	479.58M	601.50M	420.77M	483.46M	-	717.87M	687.40M	-339.70M	559.65M	1.64B
Diluted EPS	0.89	1.56	1.45	2.68	1.55	0.64	1.11	1.86	0.23	-1.58	3.90	1.29	1.25	1.07	1.84	0.13	1.43	0.63	0.90	4.64	1.41	-23.74	1.81	2.10	1.40	2.13	2.59	1.92	2.33	2.13	2.35	2.98	2.09	2.42	-	3.68	3.52	-1.75	2.87	8.40

Profit & Loss (Annual)

Figures in USD.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Revenue	65.67B	70.19B	71.76B	77.78B	78.70B	78.08B	87.96B	119.57B	135.96B	146.85B	153.14B	167.94B	179.59B	189.89B	-	238.59B	262.17B	293.96B	321.33B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	230.29B	253.21B	284.05B	309.85B
Gross Profit	2.22B	2.05B	2.10B	2.33B	2.46B	2.63B	2.51B	2.98B	3.53B	4.27B	4.55B	4.61B	5.14B	5.19B	-	8.30B	8.96B	9.91B	11.48B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.54B	6.27B	6.75B	7.54B
Operating Income	788.74M	827.86M	883.75M	1.09B	1.19B	1.30B	898.40M	782.09M	422.22M	1.53B	1.06B	1.44B	1.11B	-5.14B	-	2.75B	2.69B	3.16B	3.93B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.10B	3.37B	3.37B	3.75B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	210.67M	228.93M	248.68M	419.75M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.18B	2.16B	2.00B	2.26B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	516.52M	428.26M	484.70M	690.52M
Net Income	469.17M	250.56M	503.40M	636.75M	706.62M	718.99M	433.71M	274.23M	-138.16M	1.43B	364.48M	1.66B	855.37M	-3.41B	-	1.70B	1.75B	1.51B	1.55B
Diluted EPS	1.25	0.77	1.66	2.22	2.54	2.80	1.84	1.16	-0.63	6.32	1.64	7.53	4.04	-16.65	-	8.04	8.53	7.53	7.96

Compounded Sales Growth

5 Years:	10.43%
1 Year:	3.80%

Compounded Profit Growth

5 Years:	-2.92%
1 Year:	128.30%

Stock Price Performance

1 Year:	-6.81%
6 Months:	-27.83%
3 Months:	-27.45%
1 Month:	-13.31%

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2006	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Oct 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Assets	-	-	12.22B	13.57B	14.43B	14.98B	15.44B	18.92B	21.53B	27.96B	33.64B	35.32B	37.67B	-	39.17B	44.27B	-	56.56B	62.56B	67.10B	76.59B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.59B	42.80B	47.72B	52.24B
Cash & Equivalents	1.26B	640.20M	878.11M	1.01B	1.66B	1.83B	1.07B	1.23B	1.81B	2.17B	2.74B	2.44B	2.49B	-	3.37B	4.60B	-	3.39B	2.59B	3.13B	4.36B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.56B	17.45B	19.00B	20.49B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.45B	20.91B	23.87B	25.23B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.49B	61.89B	66.31B	74.84B
Current Liabilities	-	-	8.17B	9.48B	9.91B	10.88B	11.27B	14.87B	17.25B	21.58B	25.28B	26.82B	27.87B	-	29.58B	33.85B	-	43.48B	48.83B	54.28B	57.82B
Long Term Debt	-	-	1.19B	1.18B	1.34B	972.86M	1.40B	1.40B	2.00B	3.49B	3.58B	3.43B	4.16B	400.00M	4.03B	3.62B	-	4.63B	4.15B	3.81B	7.54B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.70B	4.79B	4.39B	7.66B
Total Equity	4.14B	3.10B	2.71B	2.72B	2.95B	2.87B	2.45B	2.31B	1.94B	616.39M	2.13B	2.06B	2.93B	-	2.88B	-1.02B	-	-211.56M	522.00M	645.94M	1.51B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	292.70M	294.82M	296.17M	297.40M

Cash Flows (Annual)

Figures in USD.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Operating Cash Flow	1.21B	737.07M	783.76M	1.11B	1.17B	1.31B	788.12M	1.46B	3.92B	3.18B	1.50B	1.41B	2.34B	2.21B	-	2.70B	3.91B	3.48B	3.88B
Investing Cash Flow	-674.44M	163.42M	-148.35M	-184.37M	-212.42M	-947.95M	117.26M	-384.15M	-2.93B	-3.17B	-498.04M	-1.11B	-375.83M	-379.87M	-	-368.44M	-2.60B	-618.10M	-4.98B
Financing Cash Flow	-1.15B	-662.58M	-504.16M	-275.44M	-787.72M	-1.12B	-740.99M	-502.99M	-632.13M	565.07M	-1.31B	-242.87M	-1.09B	-603.62M	-	-1.75B	-2.22B	-2.33B	2.25B
Capital Expenditure	-111.28M	-137.31M	-145.84M	-176.47M	-156.14M	-133.29M	-202.45M	-264.46M	-231.59M	-464.62M	-466.40M	-336.41M	-310.22M	-369.68M	-	-496.32M	-458.36M	-487.17M	-667.98M
Free Cash Flow	1.10B	599.76M	637.93M	932.15M	1.01B	1.17B	585.67M	1.20B	3.69B	2.71B	1.04B	1.07B	2.03B	1.84B	-	2.21B	3.45B	3.00B	3.21B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	581.87M	-913.41M	535.60M	1.15B
Share Buybacks	1.43B	679.68M	450.35M	470.36M	840.58M	1.16B	484.18M	753.93M	1.86B	2.27B	329.93M	639.24M	674.03M	420.45M	82.15M	483.70M	1.18B	1.49B	435.47M

Ratios (Annual)

Figures in %.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Gross Margin %	3.4%	2.9%	2.9%	3.0%	3.1%	3.4%	2.9%	2.5%	2.6%	2.9%	3.0%	2.7%	2.9%	2.7%	-	3.5%	3.4%	3.4%	3.6%
Operating Margin %	1.2%	1.2%	1.2%	1.4%	1.5%	1.7%	1.0%	0.7%	0.3%	1.0%	0.7%	0.9%	0.6%	-2.7%	-	1.2%	1.0%	1.1%	1.2%
Net Margin %	0.7%	0.4%	0.7%	0.8%	0.9%	0.9%	0.5%	0.2%	-0.1%	1.0%	0.2%	1.0%	0.5%	-1.8%	-	0.7%	0.7%	0.5%	0.5%
ROE %	15.1%	9.2%	18.5%	21.6%	24.6%	29.3%	18.8%	14.1%	-22.4%	67.1%	17.7%	56.5%	29.7%	334.5%	-	-803.0%	334.3%	233.6%	103.1%
ROCE %	-	20.4%	21.6%	24.1%	29.0%	31.2%	22.2%	18.3%	6.6%	18.3%	12.5%	14.7%	11.6%	-49.3%	-	21.0%	19.6%	24.6%	21.0%

Shareholding Pattern

Insiders

4.23%

Institutions

98.11%

Public Float

102.44%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	10.25%	19.94M	$5.37B
2	Vanguard Capital Management LLC	6.33%	12.31M	$3.32B
3	Vanguard Portfolio Management LLC	4.93%	9.59M	$2.58B
4	State Street Corporation	4.72%	9.19M	$2.48B
5	Price (T.Rowe) Associates Inc	3.76%	7.32M	$1.97B
6	FMR, LLC	3.44%	6.69M	$1.80B
7	T. Rowe Price Investment Management, Inc.	3.24%	6.29M	$1.70B
8	Geode Capital Management, LLC	2.86%	5.57M	$1.50B
9	JPMORGAN CHASE & CO	2.51%	4.89M	$1.32B
10	Wellington Management Group, LLP	2.34%	4.55M	$1.23B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COR

No recent headlines available.

COR · Healthcare

Cencora, Inc.

About

Key Facts

Sector	Healthcare
Industry	Medical Distribution
Headquarters	United States
Employees	47,000
Website	https://www.cencora.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Cencora, Inc. COR SPX

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More